Expanded IFPMA Code of Practice for pharma industry goes into effect around the world
The International Federation of Pharmaceutical Manufacturers and Associations’ (IFPMA) expanded Code of Practice has taken effect around the world. Governing how companies interact with healthcare professionals, medical institutions and patient organizations, this new code has been adopted by all IFPMA member companies and member associations.
“Advancing medical knowledge and improving global public health depend on regular information-sharing interactions between the medical community and pharmaceutical companies. These exchanges ensure patients benefit from the most up-to-date information regarding medicines,” said Eduardo Pisani, IFPMA Director General. “Ensuring that governments, healthcare providers and patients are confident that interactions with our members are conducted to the highest ethical and professional standards is our commitment.”
In March, IFPMA announced a six-month period for members to adopt the updated code. Beyond addressing interactions, the code now also includes high-level guiding principles for practice; a clear distinction between gifts, promotional aids and items of medical utility; guidance for supporting continuing medical education; and a provision on disclosure of clinical trials information. The code continues to provide guidance for filing complaints and prohibits pre-approval promotional activities for pharmaceutical products, company-sponsored entertainment at events, and providing or offering personal gifts to healthcare professionals.
IFPMA represents research-based pharmaceutical companies and associations across the globe with 1.3 million employees worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions to improve global health.